Summary & Overview
HCPCS J9033: Injection, bendamustine hydrochloride, 1 mg
HCPCS Level II code J9033 denotes the injectable chemotherapy agent bendamustine hydrochloride, billed per 1 mg unit. As a widely used cytotoxic drug for hematologic malignancies, accurate coding with J9033 affects medication billing, inventory control, and aggregation of chemotherapy utilization data nationally. This code matters to providers, payers, and pharmacy services because it ties drug acquisition, billing units, and site-of-care charges to a standardized HCPCS identifier.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for bendamustine use, common sites of service where J9033 is billed, and the types of benchmarks and policy topics typically associated with HCPCS drug codes (unitization, site-of-service considerations, and payer coverage variances). The publication also highlights common modifier usage and practical billing considerations relevant to infusion services.
This national-level summary is intended to help billing managers, pharmacists, and policy analysts understand what J9033 represents, which payers are commonly involved, and what categories of information — including reimbursement benchmarks, policy updates, and clinical context — are covered in the full publication. Data not available in the input.
Billing Code Overview
HCPCS Level II code J9033 describes an injection of bendamustine hydrochloride, 1 mg. This code represents administration of the cytotoxic chemotherapy agent bendamustine in a quantified single-milligram unit.
Service type: Chemotherapy drug administration (intravenous infusion or injection)
Typical site of service: Outpatient infusion center, hospital outpatient department, or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old adult diagnosed with chronic lymphocytic leukemia (CLL) or indolent non-Hodgkin lymphoma who presents to an outpatient oncology infusion center for chemotherapy. The physician orders J9033 (bendamustine hydrochloride) dosed per body surface area. The clinical workflow: pre-infusion nursing assessment (vitals, weight, review of laboratory values including CBC and chemistry panel), verification of consent and chemotherapy plan by the oncology provider, pharmacy preparation and sterile compounding of the specified milligram dose, bedside administration via intravenous infusion per protocol (often diluted and infused over 30–60 minutes depending on regimen), continuous monitoring for infusion reactions, post-infusion observation for delayed hypersensitivity, documentation of lot numbers and discard using modifier JW when wastage occurs, and scheduling of follow-up labs and oncology visits. Typical site of service is an outpatient infusion center or hospital outpatient department; occasional inpatient administration occurs for patients requiring admission.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered to any patient | Use when partial vial waste is discarded after compounding or administration |